GSK forecasts slower sales growth in 2026
Published on 02/04/2026 at 07:26 am GMT
Reuters
Share
Share
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,182.50 GBX | +0.81% |
|
+0.97% | +19.48% |
| 02-13 | GSK : Receives a Buy rating from Jefferies | ZD |
| 02-13 | Bernstein, Barclays and Deutsche lower Relx | AN |
![Luke Miels](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Luke Miels is currently Chief Executive Officer at GSK Plc since 2026, Director at ViiV Healthcare Co., and Member of the Singapore Economic Development Board.
Former roles include Executive VP-Global Portfolio & Product Strategy at AstraZeneca PLC and Regional VP-Asia Pacific & Pharmaceuticals Division at Roche Pharmaceuticals, Inc. Education includes an MBA from Macquarie University and an undergraduate degree from Flinders University.
Employees
68,629
Sector
Pharmaceuticals
Calendar
Trader
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
AA
Sell
Buy
Mean consensus
HOLD
Number of Analysts
22
Last Close Price
21.65GBP
Average target price
20.00GBP
Spread / Average Target
-7.60%
Quarterly revenue - Rate of surprise
- Stock Market
- Stock Market News
- GSK forecasts slower sales growth in 2026
Select your edition
All financial news and data tailored to specific country editions
